Table 4 Further applications of the rocking motion bioreactor
From: Lymphocyte expansion in bioreactors: upgrading adoptive cell therapy
Author - Year | Type | Cell | Disease | Target | Expansion | Functional highlights |
|---|---|---|---|---|---|---|
Hami [98] - 2004 | Pre-clinical | T cell | Chronic lymphocytic leukemia | T cells from Chronic lymphocytic leukemia patients | 400 fold in 13 days | High in vitro activity and T cell receptor repertoire restored after expansion. |
Hollyman [99] - 2009 | Pre-clinical | T cell | Chronic lymphocytic leukemia | T cells from Chronic lymphocytic leukemia patients | 87–668 fold in 13–18 days | Transduced and expanded T cells were able to eradicate the tumors in 90% of a mice population; release criteria were met |
Andersen [109] - 2016 | Clinical | TIL | Metastatic Melanoma | Tumor-Infiltrating Lymphocytes from Patients with Metastatic Melanoma | 2856–9975 fold in 13–36 days | Tumor regression was achieved and associated with a higher absolute number of infused tumor-reactive T cells |
Vavrova [101] - 2016 | Pre-clinical | T cell | Prostate Cancer | Prostate cancer reactive T cell effectors | 6 fold in 8 days | Significantly greater cytotoxicity against LNCaP cells after expansion. |
Bjoern [110] - 2017 | Pre-clinical | TIL | Metastatic Melanoma | Effect of Ipilimumab in metastatic melanoma derived T cells | – | Ipilimumab induced marked changes in T cell infiltrates, which can still be detected despite heavy in vitro expansion. |
O’hanlon [102] - 2017 | Research | T cell | Non-specific | 19F labeling for T cells | – | Cellular viability was maintained; ∼90% of the T cell preparation was labeled with reagent |